in

Johnson & Johnson’s Covid-19 vaccine will cost 200 pesos

The race to generate and put on the market an effective vaccine against Covid-19 seems to be closer and closer to finding an end and while these are happening, the next big question is the costs that these drugs will have that promise to restore order. In this context, Johnson & Johnson has announced the price that its vaccine will have as well as the approximate date of arrival.

The pharmaceutical company Janssen, owned by the multinational Johnson & Johnson, anticipated that the coronavirus vaccine, created by the laboratory and which is currently in phase III testing, is expected to reach the market no later than the second quarter of the year. year with a price not higher than 10 dollars, that is, about 200 pesos.

This information was released by the Vice President of the Executive Committee of Johnson & Johnson, Joaquin Duato, who in the framework of a conference at the Sectorial Meeting of the Health Sector, organized by IESE Business School, with the collaboration of the consulting firm McKinsey & Company, pointed out that it is expected to guarantee the vaccine “Sometime in the first or second semester of 2021”.

This happens when the first results from Pfizer and Moderna have reported an efficiency of 95 percent.

According to the manager, the laboratory is working on the supply chain to be able to deliver billion vaccines in 2021 through a collaborative network.

“During the next six months there will be good news, we will be able to see how these effective vaccines will be available to the public,” said Duato, while saying that they will seek to “guarantee access to the vaccine in all territories, the price will not be more $ 10 per vaccine. “

While the price of the vaccine is attractive and could put Johnson & Johnson in a prime position, what actually puts the drugmaker a step ahead of its competitors are the advantages its drug delivers in terms of transportation and storage.

As it is a single-dose vaccine, large warehouses are not needed to protect the second shots for the population.

Added to this is that, according to the company itself, the vaccine can be stored at refrigerator temperature for three months, much longer than Pfizer’s, which requires deep freezing for long-term storage.

This would solve one of the problems that DHL was already warning about with regard to the distribution of vaccines in the world. The conclusions released by this company in recent weeks were clear: access would not be guaranteed for at least two-thirds of the world’s population.